Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD) ((AU-ROOAD))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03824197
Recruitment Status : Completed
First Posted : January 31, 2019
Last Update Posted : August 2, 2021
Information provided by (Responsible Party):
Amal Kaddoumi, Auburn University

Brief Summary:

Until now there is no medical treatment and/or intervention that can slow, stop or reverse the underlying neurodegenerative of Alzheimer's disease (AD). The goal of this study is to demonstrate "Oleocanthal rich-extra-virgin olive oil (EVOO) consumption stops or delay mild cognitive impairment conversion to AD by restoring the blood-brain barrier (BBB) function in humans".

Specific Aims:

  1. Evaluate effect of EVOO on the brain function by functional MRI (fMRI) imaging, and BBB function by dynamic contrast-enhanced MRI (DCE-MRI).
  2. Evaluate effect of EVOO on cognitive function and on selected biomarkers

Condition or disease Intervention/treatment Phase
Alzheimer Disease Cerebral Amyloid Angiopathy Other: EVOO Other: OO Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Extra-virgin Olive Oil Prevents Mild Cognitive Impairment Conversion to Alzheimer's Disease
Actual Study Start Date : May 7, 2019
Actual Primary Completion Date : December 31, 2020
Actual Study Completion Date : December 31, 2020

Arm Intervention/treatment
EVOO-phenol high
Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
Other: EVOO
Extra-virgin olive oil that is rich with oleocanthal and other phenols.
Other Name: OC-rich EVOO

OO-phenol low
Olive oil with low phenolic content that will be added to daily diet
Other: OO
Olive oil low in oleocanthal and other phenols.
Other Name: Olive oil

Primary Outcome Measures :
  1. Effect of olive oil on the BBB intactness [ Time Frame: 6 months ]
    Will be evaluated by DCE-MRI

  2. Effect of olive oil on the brain activity [ Time Frame: 6 months ]
    Will be evaluated by fMRI

Secondary Outcome Measures :
  1. Cognitive function [ Time Frame: 6 months ]
    A battery of cognitive tasks to assess memory

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Men and women, experiencing mild cognitive impairment with:

  1. Mini-Mental State Exam (MMSE) scores between 18-30 (based on education level
  2. memory complaint, have objective memory loss measured by education adjusted scores on Wechsler Memory Scale Logical Memory VI
  3. Clinical Dementia Rating (CDR) score 0.5.

Exclusion Criteria:

  1. Subjects with contradictions for MRI include: the presence of metal or electronic devices such as metallic joint prostheses, artificial heart valves, an implantable heart defibrillator, a pacemaker, metal clips, cochlear implants, a bullet, shrapnel or any other type of metal fragment; breathing problems or disorders, claustrophobia, inner ear disorders, vertigo or dizziness, tattoos or permanent makeup that contains metal, and body piercing jewelry that cannot be removed.
  2. Subjects will be excluded if they are smokers
  3. Subjects who have have clinically important medical or neuropsychiatric comorbidity.
  4. Subjects who have renal problems or are allergic to the MRI contrast agent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03824197

Layout table for location information
United States, Alabama
Auburn University
Auburn, Alabama, United States, 36849
Sponsors and Collaborators
Auburn University
Layout table for investigator information
Principal Investigator: Amal Kaddoumi, PhD Auburn University
Layout table for additonal information
Responsible Party: Amal Kaddoumi, Professor, Auburn University Identifier: NCT03824197    
Other Study ID Numbers: 18-446 MR 1901
First Posted: January 31, 2019    Key Record Dates
Last Update Posted: August 2, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy, Familial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Proteostasis Deficiencies
Metabolic Diseases
Cerebral Arterial Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Cerebral Small Vessel Diseases
Amyloidosis, Familial
Metabolism, Inborn Errors
Genetic Diseases, Inborn